Carr Emily S, Brown Shannon C, Fiala Katherine H
Department of Dermatology, Baylor Scott & White Health, Texas A&M Health Science Center College of Medicine, Temple, Texas, 76508.
Dermatol Ther. 2017 May;30(3). doi: 10.1111/dth.12477. Epub 2017 Feb 17.
Vemurafenib is a selected BRAF kinase inhibitor approved for treating metastatic or unresectable melanoma, which has numerous cutaneous side effects unfortunately, including three previously reported cases of asymptomatic areola and/or nipple hyperkeratosis. We present the first case of painful bilateral nipple hyperkeratosis secondary to vemurafenib in an 84-year-old woman. She was successfully treated with tretinoin 0.05% cream that allowed her to comfortably continue treatment. With increased awareness of this condition, we found a second case of asymptomatic nipple hyperkeratosis secondary to vemurafenib in our clinic. As this medication gains acceptance for treatment of metastatic melanoma, it is imperative that dermatologists are aware of this potentially uncomfortable side effect that can result in decreased compliance and impaired quality of life.
维莫非尼是一种经批准用于治疗转移性或不可切除黑色素瘤的选择性BRAF激酶抑制剂，遗憾的是它有许多皮肤副作用，包括先前报道的3例无症状乳晕和/或乳头角化过度病例。我们报告了首例84岁女性因维莫非尼导致双侧乳头角化过度伴疼痛的病例。她使用0.05%维甲酸乳膏成功治愈，得以舒适地继续治疗。随着对这种情况的认识增加，我们在诊所又发现了1例因维莫非尼导致无症状乳头角化过度的病例。由于这种药物在转移性黑色素瘤治疗中越来越被接受，皮肤科医生必须意识到这种可能令人不适的副作用，它可能导致依从性下降和生活质量受损。
